Enhanced anti-colon cancer efficacy of 5-fluorouracil by epigallocatechin-3- gallate co-loaded in wheat germ agglutinin-conjugated nanoparticles

Wang, Ruoning; Huang, Jinyu; Chen, Jian; Wang, Honglan; Qiao, Hongzhi; Chen, Zhipeng; Hu, Lihong; Di, Liuqing; Li, Junsong

doi:10.1016/j.nano.2019.102068

Cited by 45 publications

(19 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A recent preclinical study revealed that EGCG attenuated DOX-induced cardiotoxicity in rats (Saeed et al, 2015). Besides, reports also showed that EGCG could work as an adjuvant in cancer treatment to enhance the efficacy of chemotherapy, such as EGCG inhibited DNA repair and enhanced cisplatin sensitivity in human cancer cells both in vitro and in vivo (Heyza et al, 2018), and the 5-FU and EGCG coloaded nanoparticles could sustained drug release, and enhanced cellular uptake, thus exhibited superior anti-tumor activity and pro-apoptotic efficacy in vivo against colon cancer (Wang et al, 2019).…”

Section: Discussionmentioning

confidence: 99%

EGCG Enhanced the Anti-tumor Effect of Doxorubicine in Bladder Cancer via NF-κB/MDM2/p53 Pathway

Luo

Zhu

Zhao

et al. 2020

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Doxorubicin (DOX), the first-line chemotherapy for bladder cancer, usually induces side effects. We previously demonstrated that green tea polyphenol EGCG had potent anti-tumor effect in bladder cancer via down regulation of NF-κB. This study aimed to investigate the additive/synergistic effect EGCG and DOX against bladder cancer. Our results demonstrated that the combined use of DOX and EGCG inhibited T24 and SW780 cell proliferation. EGCG enhanced the apoptosis induction effect of DOX in both SW780 and T24 cells and resulted in significant differences. Besides, EGCG promoted the inhibitory effect of DOX against bladder cancer cell migration. In addition, the in vivo results demonstrated that DOX in combination with EGCG showed the most potent anti-tumor effects among DOX, EGCG and DOX+EGCG treatment groups. Further mechanistic studies determined that the combination of DOX and EGCG inhibited phosphorylated NF-κB and MDM2 expression, and up-regulated p53 expression in tumor, as assessed by western blot and immunohistochemistry. Western blot in SW780 cells also confirmed that the combined use of EGCG and DOX caused significant increase in p53, p21, and cleaved-PARP expression, and induced significant inhibition in phosphorylated NF-κB and MDM2. When NF-κB was inhibited, the expression of p53 and p-MDM2 were changed, and the combination of DOX and EGCG showed no obvious effect in transwell migration and cell viability. In conclusion, the novel application of chemotherapy DOX and EGCG demonstrated potent anti-tumor, anti-migration and anti-proliferation effects against bladder cancer. EGCG enhanced the anti-tumor effect of DOX in bladder cancer via NF-κB/MDM2/p53 pathway, suggesting the potential clinical application against bladder cancer patients.

show abstract

Section: Discussionmentioning

confidence: 99%

EGCG Enhanced the Anti-tumor Effect of Doxorubicine in Bladder Cancer via NF-κB/MDM2/p53 Pathway

Luo

Zhu

Zhao

et al. 2020

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

show abstract

“…The nanoparticle has exhibited a superior anti-cancer activity as well as pro-apoptotic efficacy compared to free drugs and nanoparticles alone. 30 Chitosan-based 5-fluorouracil nanoparticles of around 169.2 nm to 259.8 nm in size and the tumor inhibition rates of high, medium, low concentration group of drug-loaded nanoparticles was found to be 62.05%, 48.79% and 36.14%, respectively. 31 In this study, we simultaneously incorporated Sorafenib and 5-fluorouracil drugs using chitosan nanoparticles as the host to form chitosan sorafenib/5-fluorouracil drug nanoparticles (SF/5FU-CS NPs) and their conjugation with FA, folate-chitosan conjugated sorafenib/5-fluorouracil drug nanoparticles (SF/5FU-CS-FA NPs).…”

Section: Introductionmentioning

confidence: 94%

Sorafenib and 5-Fluorouracil Loaded Dual Drug Nanodelivery Systems for Hepatocellular Carcinoma and Colorectal Adenocarcinoma

Ruman

Buskaran

Saifullah

et al. 2021

Preprint

View full text Add to dashboard Cite

Purpose: Here, we reported the sysnthesis of two clinically used drugs, 5-fluorouracil (5FU) and Sorafenib (SF)-loaded in chitosan nanoparticles and their priliminary study of therapeutics effect on hepatocellular carcinoma and colorectal adenocarcinoma cell lines. We have formulated chitosan nanoparticles (CS NPs) loaded dual (SF and 5-FU) drugs nanodelivery system for SF/5FU-CS NPs and their coating version with folic acid (FA) for SF/5FU-CS-FA NPS. Human hepatocellular carcinoma (HepG2) and colorectal adenocarcinoma (HT29) cell lines were selected for in vitro cytotoxicity studies to evaluate the preliminary anticancer efficacy of both nanoparticles.Characterization: The physiochemical characterization of SF/5FU-CS NPs and SF/5FU-CS-FA NPs were investigated by DLS, FESEM, HRTEM, EDX, XRD, TGA, FTIR, and HPLC methods.Results: DLS study has shown the size of SF/5FU-CS and SF/5FU-CS-FA nanoparticles were about 78±14 nm and 142±25 nm, respectively. HRTEM and FESEM studies confirmed the spherical shape with size of 60-70nm for SF/5FU-CS and 90-150 nm for SF/5FU-CS-FA NPs. The XRD results indicated the drug loading and folate-coating comfirmation. FTIR peaks confirmed the presence of drugs in the nanoparticles, as well as folate-coating on the surface of the nanoparticles. TGA results demonstrated the thermostability of both nanoparticles. The release profiles of SF and 5FU from the two designed NPs were found to be in a sustained manner according to the pseudo-second-order kinetics model indicating a good delivery system for tumor cells. The cytotoxicity studies confirmed the better anti-cancer activity of the nanoparticles compared to the free 5-fluorouracil and sorafenib against liver cancer cells, HepG2 and colon cancer cells, HT29. Conversely, both NPs were found not toxic towards normal human dermal fibroblast cells (HDF) cells.

show abstract

“…Due to the active-targeting capacity, these NPs delivered a significantly higher amount of EGCG and 5-FU to the colon tumor. Consequently, these NPs displayed the strongest anti-colon tumor effect in vivo with less systemic toxicity compared to other types of NPs [ 168 ].…”

Section: Nanodelivery Of Green Tea Catechinsmentioning

confidence: 99%

Advances in Nanodelivery of Green Tea Catechins to Enhance the Anticancer Activity

Jiang

2021

Molecules

View full text Add to dashboard Cite

Cancer is one of the leading causes of death globally. A variety of phenolic compounds display preventative and therapeutic effects against cancers. Green teas are rich in phenolics. Catechins are the most dominant phenolic component in green teas. Studies have shown that catechins have anticancer activity in various cancer models. The anticancer activity of catechins, however, may be compromised due to their low oral bioavailability. Nanodelivery emerges as a promising way to improve the oral bioavailability and anticancer activity of catechins. Research in this area has been actively conducted in recent decades. This review provides the molecular mechanisms of the anticancer effects of catechins, the factors that limit the oral bioavailability of catechins, and the latest advances of delivering catechins using nanodelivery systems through different routes to enhance their anticancer activity.

show abstract

Enhanced anti-colon cancer efficacy of 5-fluorouracil by epigallocatechin-3- gallate co-loaded in wheat germ agglutinin-conjugated nanoparticles

Cited by 45 publications

References 39 publications

EGCG Enhanced the Anti-tumor Effect of Doxorubicine in Bladder Cancer via NF-κB/MDM2/p53 Pathway

EGCG Enhanced the Anti-tumor Effect of Doxorubicine in Bladder Cancer via NF-κB/MDM2/p53 Pathway

Sorafenib and 5-Fluorouracil Loaded Dual Drug Nanodelivery Systems for Hepatocellular Carcinoma and Colorectal Adenocarcinoma

Advances in Nanodelivery of Green Tea Catechins to Enhance the Anticancer Activity

Contact Info

Product

Resources

About